Novo Nordisk B A/S
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Novo Nordisk B A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
/ 
Novo Nordisk A/S is a Danish multinational pharmaceutical company specialising in treatments for diabetes, obesity, and other severe chronic diseases. Founded in 1923 and headquartered in Bagsværd, Denmark, the company is one of the largest producers of insulin and a global leader in diabetes care.
Its product portfolio includes insulin, GLP-1 receptor agonists, and related devices for managing diabetes, as well as medicines for obesity, haemophilia, and growth disorders. Novo Nordisk has played a significant role in advancing therapies for metabolic diseases and continues to expand research into cardiovascular and rare conditions.
The company operates production facilities in several countries, with key research and development centres located in Denmark, the United States, China, the United Kingdom and India. Its medicines are marketed in more than 170 countries.
Novo Nordisk is listed on the Nasdaq Copenhagen stock exchange and also has American Depositary Receipts (ADRs) traded on the New York Stock Exchange (NYSE).
Saxo provides this content for general information only. It is not intended as personal advice, an offer, or a recommendation. Saxo does not guarantee accuracy or completeness and accepts no liability for losses. Consider obtaining independent advice before any investment decision.
Frequently asked questions
To buy Novo Nordisk B A/S stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Novo Nordisk B A/S by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Novo Nordisk B A/S is NOVOb:xcse. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Novo Nordisk B A/S has its primary listing on NASDAQ OMX Copenhagen. You can trade Novo Nordisk B A/S with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Novo Nordisk B A/S is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Novo Nordisk B A/S as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Novo Nordisk B A/S.